Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Danvatirsen - AstraZeneca/Ionis Pharmaceuticals

X
Drug Profile

Danvatirsen - AstraZeneca/Ionis Pharmaceuticals

Alternative Names: AZD-9150-sodium; AZD9150; Danvatirsen-sodium; IONIS-STAT3-2.5Rx; IONIS-STAT3Rx; ISIS-345794; ISIS-481464; ISIS-STAT3-2.5Rx; ISIS-STAT3Rx; STAT3Rx

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company; Isis Pharmaceuticals
  • Developer Acerta Pharma; AstraZeneca; Flamingo Therapeutics; Ionis Pharmaceuticals; MedImmune; Montefiore Medical Center; National Cancer Institute (USA)
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Colorectal cancer; Head and neck cancer; Malignant ascites; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Phase I/II Liver cancer; Non-Hodgkin's lymphoma
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
  • No development reported Diffuse large B cell lymphoma

Most Recent Events

  • 01 Oct 2023 Phase-I clinical trials in Acute myeloid leukaemia (In volunteers, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT05986240)
  • 01 Oct 2023 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, In volunteers, Monotherapy) in USA (IV) (NCT05986240)
  • 01 Oct 2023 Phase-I clinical trials in Myelodysplastic syndromes (In volunteers, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT05986240)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top